Achiko Announces Convertible Loan Extension

0
48

[ad_1]

ZURICH, 18 June 2021 (GLOBUS NEWS) – Achiko AG (SWX: ACHI, ISIN CH0522213468) (“Achiko”, “Company”) successfully renewed its 900,000 Swiss francs subordinated convertible loan agreement dated 8 March 2021 to CHF 1,650,000, thereby providing Achiko with an additional CHF 750,000 for use in product development, sales and marketing and the required working capital with a focus on AptameX as well as Teman Sehat product launch in Indonesia at the beginning of the third quarter of 2021.

The additional amount of the convertible loan is accompanied by the issuance of an additional 1,500,000 warrants. Each warrant entitles you to purchase one registered share of the Company with a maturity period from November 2, 2021 to 360 years.th the day after the date of issue of the warrants and with a strike price of CHF 0.23 (subject to normal adjustments).

Following on from earlier production and supply of AptameX test kits to Indonesia and favorable preliminary results for Covid-19 diagnostic testing with a sensitivity of 77.59% (95% confidence interval (CI): 75.94 – 79.24) on a CT scan of 28. 3, Achiko is now moving into position herself to capitalize on the promise of her own test suite.

“We are delighted to receive this additional funding, which will complete the development of AptameX’s Covid-19 diagnostic test kit and increase sales and marketing to launch our product in Indonesia at the start of the third quarter,” said Stephen Gough, CEO. Achiko.

This funding milestone allows Achiko to underline its commitment to developing a fast, accurate, and cost-effective solution for diagnosing people with Covid-19. Achiko’s investments in AptameX and Teman Sehat technologies, as well as his joint venture agreements, offer an unusual solution to combat further outbreaks of Covid-19, especially in developing countries, in light of the rapid increase in Delta cases. identified in India.

AptameX is certified for distribution in Indonesia through joint venture partner Achiko. PT Indonesia Farma Medis (“IFM”), and the Company is currently moving towards the completion of final validation testing and product registration, ensuring the kit is available for testing in the third quarter of 2021.

Achiko is committed to providing pandemic insurance services to 270 million residents across 17,000 islands. The potential is that Achiko will test perhaps 2% of the country’s population by the end of the year, which equates to approximately 5.4 million people with 3-5 tests per month, realizing a possible initial production of 15-25 million tests per month.

ABOUT ACHIKO AG
Achiko creates and develops new innovations in healthcare technology through its biotech division AptameX and its digital mobile healthcare subsidiary Teman Sehat. The company has created a unique telemedicine capability that provides user-friendly diagnostic testing integrated with a digital passport solution for managing Covid-19.

AptameX consists of DNA aptamer-based technology that is cost-effective, chemically synthesized, and widely applicable in the emerging healthcare diagnostic field. Together with the Teman Sehat digital mobile health app, Achiko is developing potential technologies that aim to provide fast and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications. AptameX technology is licensed under Regenacellx.sl and Achiko has exclusive commercialization rights.

Achiko is headquartered in Zurich with offices in Hong Kong, Jakarta, Seoul and Singapore.

More information can be found on the website www.achiko.com

If you have any questions regarding the Company, please contact us.

Media contacts:

ACHIKO AG
Investor relations
E: ir@achiko.com

Switzerland and the whole world
Markus Balog
Farner Consulting Ltd.
E: achiko@farner.ch
T: +41 44 266 67 67

DENIAL OF RESPONSIBILITY

This message contains, directly or indirectly, certain forward-looking statements regarding Achiko AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors that could cause Achiko AG’s actual results, financial condition, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. statements. Achiko AG provides this message from this date and does not undertake to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

[ad_2]

Source link